Abstract

Cytokines play an important role in modulating inflammation during viral infection, including hepatitis C virus (HCV) infection. Genetic polymorphisms of cytokines can alter the immune response against this infection. The objective of this study was to investigate the possible association between chronic hepatitis C virus infection susceptibility and cytokine gene polymorphism for interleukin-10 (IL-10) rs1800896 and rs1800871, interleukin 6 (IL-6) rs1800795, TNF-α rs1800629, and TGF-β1 rs1800471 in Malay male drug abusers. The study was conducted on 76 HCV-positive (HP) male drug abusers and 40 controls (HCV-negative male drug abusers). We found that there were significant differences in the frequencies of genotype for IL-10 rs1800871 (p = 0.0386) and at the allelic level for IL-10 rs1800896 A versus G allele (p = 0.0142) between the HP group and the control group. However, there were no significant differences in gene polymorphism in interleukin 6 rs1800795, TNF-α rs1800629 and TGF-β1 rs1800471. These findings suggest significant associations between gene polymorphism for IL-10 rs1800871, IL-10 rs1800896 (at the allelic level) and susceptibility to HCV infection among Malay male drug abusers.

Highlights

  • Introduction published maps and institutional affilHepatitis C virus (HCV) infection is the leading cause of chronic liver disease and liver cancer

  • We investigated the association of cytokine gene polymorphisms in IL-10, interleukin 6 (IL-6), TNF-α and TGF-β1 allele with susceptibility to hepatitis C virus (HCV) infection among Malay male drug abusers in comparison to drug abusers without HCV

  • We investigated the role of the IL-6 rs1800795 SNP in chronic HCV infection and found that GG was the most common genotype, with the G allele being the most frequent in both drug abusers with chronic HCV and the control group, and there were no significant differences

Read more

Summary

Introduction

Hepatitis C virus (HCV) infection is the leading cause of chronic liver disease and liver cancer. It is estimated that the worldwide prevalence of HCV was around 1% in 2015, accounting for 71.1 million people burdened by the disease [1]. HCV is a bloodborne virus that is transmitted frequently via the usage of intravenous drugs, contributing to 60–80%. Of HCV cases in developed countries [2]. The risk of infection is significantly increased for those with a history of injection of 6 years and more [3]. Other risk factors for the spread include unscreened blood products for transfusion, unsafe sexual practices, and vertical transmission [4]. About 15–45% of patients infected with HCV spontaneously recover from the disease without any treatment, while the majority of patients develop persistent chronic HCV [5]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call